In the second of our two stories focusing on RSV, MPP is marking World Children’s Day 2026 by examining the possible moves towards RSV prevention and treatment options in low-and middle-income countries. MPP is exploring how voluntary licensing and technology transfer could support earlier, more affordable access to new RSV medicines.

Anna Turkova, Professor in Clinical Epidemiology at University College London

We speak to Anna Turkova, Professor in Clinical Epidemiology at University College London, and Julia Bielicki, Professor of Paediatric Infectious Diseases at City St. George’s, London and Professor of Paediatric Clinical Pharmacology at the University of Basel. Both are members of the Penta ID Network, an international research collaboration connecting more than 1,000 healthcare professionals and researchers worldwide. MPP and the Penta Foundation signed a Memorandum of Understanding in June 2026 to collaborate on access to RSV prevention and treatment in LMICs.

Respiratory syncytial virus (RSV) is so common that it is believed every child becomes infected by the age of two. The World Health Organization (WHO) estimates that there are approximately 3.6 million hospital admissions and around 100,000 RSV-related deaths each year.

An astonishing 97 per cent of these deaths occur in low- and middle-income countries (LMICs). But most LMICs do not have the necessary health infrastructure and systems to respond effectively to RSV infection, which can be severe enough to require hospital care. 

Factors behind high rates of RSV in LMICs

As Professor Turkova says: “Too many children remain undiagnosed and never make it to hospital and die at home. There is very little awareness in LMICs about how damaging RSV can be to children and what the public health challenge amounts to. Building awareness of RSV among parents, policy makers, and healthcare workers is very important.”

“In Africa, the preterm rate of deliveries is among the highest in the world. There’s a high proportion of children with low birth weight, children with malnutrition, children born with other diseases. These all add to the severity of infant RSV infection.”

Another key factor can also lead to high rates of RSV in LMICs: “In the global north, we tend to have very defined RSV seasonality which lasts a few months and is quite predictable,” Professor Turkova says. “But in subtropical and tropical countries, so in many LMICs, seasonality is much less predictable. RSV seasons are often longer and linked to the rainy season. Some areas have two peaks a year, and in others transmission is reported throughout the year, affecting more children.”

Julia Bielicki, Professor of Paediatric Infectious Diseases at City St. George’s, London and Professor of Paediatric Clinical Pharmacology at the University of Basel

Trial project in Africa for RSV prevention

Professor Turkova is co-leading the development of the PIPELINE-Africa-RSV project, a collaboration between 18 partners in Europe and Africa, including MPP and Penta. It has been recently submitted for EU funding. If funded, it  will include a trial comparing two RSV-prevention products in Africa – the maternal vaccine and monoclonal antibodies (mAbs) – alongside immunology and virology studies, surveillance of RSV infections, and studies of how acceptable and feasible these interventions are for parents and healthcare workers. “All of these data will feed into a health economic model and a budget tool, to help programmes decide whether introducing infant mAbs would bring benefits, for which infants, and at what cost,” Professor Turkova explains. “We will also be looking at the role of mAbs specifically for those babies and infants at high risk.”

“We now need to fill the gaps in evidence required to inform policies, through the right studies. The current cost of mAbs is challenging for LMIC interventions, and we still don’t know how well mAbs will perform in LMICs, or how they could best complement the maternal vaccine. The context in LMICs is very different from high-income countries, so not all the evidence generated there can be extrapolated for LMICs.”

MPP’s role in post-trial access to prevention products

“We also need to enable post-trial access in countries, and link the evidence to access,” Turkova continues. “We can’t just trial the product if we know it’s not going to be available. That’s where MPP’s role is so effective: for affordable access to RSV prevention in the region beyond the trial.”

Whilst emphasising the potential impact of the maternal vaccine and the beneficial changes it could bring to LMICs, Professor Turkova also stresses that mAbs could be highly effective in these countries too.

“There are two contexts where the maternal vaccine may not protect the baby,” she says. “First, some women don’t receive it at all: they present late in pregnancy, only attend for the delivery, or deliver at home. Second, some women are vaccinated but the baby is born too soon afterwards, and there isn’t enough time for the mother to build an immune response and pass protective antibodies through the placenta to her baby.”

Potential role of mAbs for vulnerable infants

“So for infants whose mothers did not receive the maternal vaccine or received it too late, or for those at high risk of severe RSV, like babies born preterm or with congenital heart disease, mAbs could provide effective prevention and could be cost effective,” she explains. “For these vulnerable infants, mAbs could be life-saving. mAbs could also have a wider role in settings where uptake of the maternal vaccine is suboptimal, and where mAbs could be built into the childhood immunization schedule.”

“It does not necessarily mean there needs to be a huge supply of these mAbs. They are likely to be more expensive than the maternal vaccine, but mAbs could still be cost effective as the cost of a prolonged hospital admission for a sick preterm child requiring respiratory  support is very high. It’s an evidence gap that needs to be studied,” she concludes.

There is currently no specific treatment for RSV, so care is supportive. As many infants and children with RSV develop hypoxaemia – low oxygen levels in the blood – oxygen supplementation is a mainstay of this care.

‘Oxygen supplementation is a very tight resource’

As Professor Bielicki makes clear: “Oxygen supplementation is a very tight resource. It’s often not available for the infants and children who might need it, which compounds the burden of RSV in LMICs. If you give it to one baby or child, you might have to ignore others who can’t receive it because it can be so limited.”

Professor Bielicki is a board member of the Penta Foundation, and her expertise lies in developing high impact treatment trials to combat infections, mostly pneumonia and neonatal sepsis. She will oversee any RSV treatment trials that might flow from the MPP-Penta collaboration, including one recently submitted as a grant application, similar to Professor Turkova’s PIPELINE-Africa-RSV trial.

Different treatments in the pipeline

“There are several treatments in the pipeline, each with different mechanisms,” Professor Bielicki says. “Those in the later stages of drug development are well tolerated and the side-effect profiles seem to be very good. They’re available as oral preparations and the formulations are appropriate for use in young children.”

“There is a need for a really pivotal trial to help us investigate and determine what their role is in LMICs. I’m very optimistic that with the right sort of support from different stakeholders such as MPP, this can be achieved and would potentially be game-changing.”

MPP can help reduce the time to implementation

Professor Bielicki stresses that MPP’s involvement could help ensure that any RSV treatments reach LMICs quickly, once evidence shows their potential role in addressing infant RSV infection. “The timelines to move all the way from evidence generation for regulatory submission, to adoption on the WHO Model List of Essential Medicines and national guidelines can be very long. These timelines are much longer when it comes to LMICs. Having plans for access with strong MPP involvement while trials are taking place can really help us shorten these timelines for children to benefit.” 

At present, however, as there is no RSV-directed treatment, RSV-typical infections, such as bronchiolitis, are often also treated with antibiotics. “This means firstly that the children are not going to get any better [since, unlike bacteria, RSV is a virus and does not respond to antibiotics],” Professor Bielicki says. “Secondly, the anti-microbial resistance (AMR) problem becomes so much worse with all the friendly bacteria in the children’s microbiome becoming depleted. An RSV-directed treatment for these children would therefore be a really strong stewardship intervention too.”

Diagnostics can become a limiting factor to access

The role of diagnostics is another element of Professor Bielicki’s focus. One of the lessons she has taken from her work on AMR is at first glance perhaps quite surprising.

“The interplay between diagnostics and treatment is very important and can be a significant barrier to access to treatment,” she explains. “If treatment is coupled tightly to diagnostics, it becomes a limiting factor for access in and of itself. That’s because patients must have access to a chain of interventions: the diagnostic intervention first, the treatment itself, and then potentially some other diagnostic to ensure that the treatment is working.” Infants and their caregivers need to go through all these steps without dropping out of care.

“Given this, as part of any trial, we want to establish whether RSV actually needs to be tested at all. Instead, RSV treatment could be administered to every baby and child presenting with lower respiratory tract infection as a matter of course. As RSV causes up to 50 per cent of childhood lower respiratory tract infections requiring hospitalisation, those patients with RSV would be successfully treated, and those without would not suffer any ‘collateral damage’, unlike antibiotic treatment.” 

RSV treatment for all children could be the best solution

“This approach would have several overlapping benefits. Firstly, there would be more recoveries from RSV, and the use of unnecessary antibiotics could be reduced substantially. As RSV antivirals would help children get better more quickly, less oxygen would be required for children in hospital. It would also obviate the ‘access blockage’ caused by diagnostics and the need to ensure they’re always available. We could potentially achieve all these things simply by prescribing anti-RSV medication to all very young children admitted to hospital with respiratory tract infection and needing oxygen.” This would not only complement RSV prevention efforts, but could also help reduce bed occupancy in overcrowded paediatric emergency and intensive care units.

Across all these health innovations to protect children, MPP aims to play a significant role with Penta in establishing access to both prevention and treatment options for RSV in LMICs. As Professor Turkova says: “There has been huge success with voluntary licences in HIV and how generic companies have been able to produce more affordable products, including paediatric formulations, at the scale needed. MPP’s expertise in voluntary licensing and post-trial access is invaluable”.

A 2025 WHO Paediatric Drug Optimization (PADO) consultative process led by the Global Accelerator for Paediatric Formulations (GAP-f) outlined priority RSV long-acting monoclonal antibodies for prevention and antiviral agents for treatment with the goal of accelerating access to child-friendly RSV interventions, particularly in LMICs. With both Penta and MPP as founding members of GAP-f and partners engaged in PADO RSV, the work presented above directly follows up on this prioritisation process.